Certara, Inc. ( (CERT) ) has released its Q1 earnings. Here is a breakdown of the information Certara, Inc. presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Certara, Inc. is a global leader in model-informed drug development, providing biosimulation software and services to biopharmaceutical companies, academic institutions, and regulatory agencies worldwide. In its first quarter of 2025, Certara reported a 10% increase in revenue, reaching $106 million, driven by strong growth in its biosimulation software segment. The company also achieved a significant turnaround in net income, reporting $4.7 million compared to a loss in the previous year. Key financial metrics showed positive trends, with software revenue up by 18% and adjusted EBITDA increasing by 20% to $34.8 million. Certara’s strategic focus on biosimulation and regulatory services continues to yield results, as evidenced by a 12% growth in total bookings. The company’s management remains optimistic about the future, reiterating its full-year financial guidance for 2025, with expectations of continued revenue growth and stable adjusted EBITDA margins.